---
created: 2025-04-13
updated: 2025-04-13T10:53
id: IcaJ*:]|Ke
specialty: obgyn
specialty_id: 84
tags:
  - source/ak-original-decks::step-2::zanki-step-2
  - "source/ak-step1-v11:": 
  - theme/amboss
  - "source/ak-step1-v11:": 
  - theme/nbme::29
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::13-gynecology::03-endometrial-cancer
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::12-reproductive::03-raloxifene,-clomiphene,-tamoxifen
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::raloxifene-and-tamoxifen
  - "source/ak-step1-v11:": 
  - theme/uworld::100-999::500-599::581
  - source/ak-step2-v11::!flag-these-cards::potential-duplicates
  - "source/ak-step2-v11::!shelf:": 
  - theme/cards-anking-did::1surgery
  - "source/ak-step2-v11:": 
  - theme/b&b::06-obgyn::gyne::12-uterine-cancer
  - "source/ak-step2-v11:": 
  - theme/ome::14-gynecology::03-endometrial-cancer
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::obgyn::uw::zanki::female-repro-breast
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::surgery::devirgilio-dorian::breast
  - "source/ak-step2-v11:": 
  - theme/subjects::obstetrics-&-gynecology::01-gynecology::uterus::pathology::endometrial-carcinoma
  - "source/ak-step2-v11:": 
  - theme/subjects::obstetrics-&-gynecology::01-gynecology::uterus::pathology::endometrial-carcinoma::pathophysiology
  - source/ak-step2-v11::original-decks::dorian::surg::devirgilio::breast
  - source/ak-step2-v11::original-decks::zanki-step-2::obgyn::female-repro-&-breast
type: flashcard
---

# Question
Tamoxifen is a selective estrogen receptor modulator associated with increased risk of **endometrial** hyperplasia/cancer

---

# Answer
due to estrogen agonist activity in endometrial and bone tissue In the breast, estrogen receptor antagonist == competitive inhibition of estradiol binding to its receptor